Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial

The Lancet 2026

View at publisher
Authors: Olivier van Minnen, Annemieke Oude Lansink‐Hartgring, Rombout B E van Amstel, Bas van den Bogaard, Jeroen J. H. Bunge, Thijs S R Delnoij, Joep M. Droogh, Laurien van Koppenhagen, Carlos V. Elzo Kraemer, Marijn Kuijpers, Jacinta J. Maas, Jesse de Metz
+13 more Marcel C G van de Poll, S. Jorinde Raasveld, Dinis dos Reis Miranda, Priya Vart, Karin M. Vermeulen, Alexander P J Vlaar, Walter M. van den Bergh, Maite M.T. van Haeren, Matty Koopmans, Marcella C.A. Müller, Dirk W. Donker, Christiaan L. Meuwese, Sakir Akin
DOI: 10.1016/s0140-6736(26)00851-2
Cited by: 1
References: 42

Fields of Study & Subjects

Mechanical Circulatory Support Devices Cardiac and Coronary Surgery Techniques Heparin-Induced Thrombocytopenia and Thrombosis

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
408
Issue
10552
Pages
357–366
Publication date
1 July 2026
Language
EN